EGFR and lung cancer: Yokota et al. (2021) developed PDOs for therapeutic screening from lung adenocarcinoma, lung adenocarcinoma lymph node metastases and EGFR-resistant lung cancer malignant pleural effusion cells using basal membrane extract. The cell culture medium was optimized for cellular purity and long-term expansion (up to 13 months). In parallel, PDOs were cultured from adjacent normal lung tissue (Sachs et al., 2019).